Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma

Ursula Matulonis, Ignace Vergote, Floor Backes, Lainie P. Martin, Scott McMeekin, Michael Birrer, Frank Campana, Yi Xu, Coumaran Egile, Sharad A Ghamande

Research output: Contribution to journalArticlepeer-review

62 Scopus citations

Fingerprint Dive into the research topics of 'Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences